Global Peptide Cancer Vaccine Market Growth 2021-2026
According to this latest study, the 2021 growth of Peptide Cancer Vaccine will have significant change from previous year. By the most conservative estimates of global Peptide Cancer Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 443.6 million in 2020. Over the next five years the Peptide Cancer Vaccine market will register a 20.5% CAGR in terms of revenue, the global market size will reach US$ 936.6 million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Cancer Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by pipeline: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide Cancer Vaccine Consumption 2016-2026
2.1.2 Peptide Cancer Vaccine Consumption CAGR by Region
2.2 Peptide Cancer Vaccine Segment by Pipeline
2.2.1 ITK-1
2.2.2 GRN-1201
2.2.3 TPIV200
2.2.4 TPIV110
2.2.5 UV1
2.2.6 Galinpepimut-S
2.2.7 TARP 27-35
2.2.8 HER-Vaxx
2.2.9 Vx-001
2.2.10 Others
2.3 Peptide Cancer Vaccine Sales by Pipeline
2.3.1 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Pipeline (2016-2021)
2.3.3 Global Peptide Cancer Vaccine Sale Price by Pipeline (2016-2021)
2.4 Peptide Cancer Vaccine Segment by Application
2.4.1 Breast Cancer
2.4.2 Lung Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.4.5 Others
2.5 Peptide Cancer Vaccine Sales by Application
2.5.1 Global Peptide Cancer Vaccine Sale Market Share by Application (2016-2021)
2.5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2016-2021)
2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2016-2021)
3 Global Peptide Cancer Vaccine by Company
3.1 Global Peptide Cancer Vaccine Sales Market Share by Company
3.1.1 Global Peptide Cancer Vaccine Sales by Company (2019-2021)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Company (2019-2021)
3.2 Global Peptide Cancer Vaccine Revenue Market Share by Company
3.2.1 Global Peptide Cancer Vaccine Revenue by Company (2019-2021)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2021)
3.3 Global Peptide Cancer Vaccine Sale Price by Company
3.4 Global Manufacturers Peptide Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Cancer Vaccine Product Location Distribution
3.4.2 Players Peptide Cancer Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Peptide Cancer Vaccine by Region
4.1 Global Peptide Cancer Vaccine by Region
4.1.1 Global Peptide Cancer Vaccine Sales by Region
4.1.2 Global Peptide Cancer Vaccine Revenue by Region
4.2 Americas Peptide Cancer Vaccine Sales Growth
4.3 APAC Peptide Cancer Vaccine Sales Growth
4.4 Europe Peptide Cancer Vaccine Sales Growth
4.5 Middle East & Africa Peptide Cancer Vaccine Sales Growth
5 Americas
5.1 Americas Peptide Cancer Vaccine Sales by Country
5.1.1 Americas Peptide Cancer Vaccine Sales by Country (2016-2021)
5.1.2 Americas Peptide Cancer Vaccine Revenue by Country (2016-2021)
5.2 Americas Peptide Cancer Vaccine Sales by Pipeline
5.3 Americas Peptide Cancer Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Cancer Vaccine Sales by Region
6.1.1 APAC Peptide Cancer Vaccine Sales by Region (2016-2021)
6.1.2 APAC Peptide Cancer Vaccine Revenue by Region (2016-2021)
6.2 APAC Peptide Cancer Vaccine Sales by Pipeline
6.3 APAC Peptide Cancer Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country (2016-2021)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country (2016-2021)
7.2 Europe Peptide Cancer Vaccine Sales by Pipeline
7.3 Europe Peptide Cancer Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide Cancer Vaccine by Country
8.1.1 Middle East & Africa Peptide Cancer Vaccine Sales by Country (2016-2021)
8.1.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2016-2021)
8.2 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline
8.3 Middle East & Africa Peptide Cancer Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Peptide Cancer Vaccine Distributors
10.3 Peptide Cancer Vaccine Customer
11 Global Peptide Cancer Vaccine Market Forecast
11.1 Global Peptide Cancer Vaccine Forecast by Region
11.1.1 Global Peptide Cancer Vaccine Forecast by Regions (2021-2026)
11.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Peptide Cancer Vaccine Forecast by Pipeline
11.7 Global Peptide Cancer Vaccine Forecast by Application
12 Key Players Analysis
12.1 Boston Biomedical
12.1.1 Boston Biomedical Company Information
12.1.2 Boston Biomedical Peptide Cancer Vaccine Product Offered
12.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Boston Biomedical Main Business Overview
12.1.5 Boston Biomedical Latest Developments
12.2 Ultimovacs
12.2.1 Ultimovacs Company Information
12.2.2 Ultimovacs Peptide Cancer Vaccine Product Offered
12.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Ultimovacs Main Business Overview
12.2.5 Ultimovacs Latest Developments
12.3 BrightPath Biotherapeutics
12.3.1 BrightPath Biotherapeutics Company Information
12.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Offered
12.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 BrightPath Biotherapeutics Main Business Overview
12.3.5 BrightPath Biotherapeutics Latest Developments
12.4 TapImmune
12.4.1 TapImmune Company Information
12.4.2 TapImmune Peptide Cancer Vaccine Product Offered
12.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 TapImmune Main Business Overview
12.4.5 TapImmune Latest Developments
12.5 Immatics
12.5.1 Immatics Company Information
12.5.2 Immatics Peptide Cancer Vaccine Product Offered
12.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Immatics Main Business Overview
12.5.5 Immatics Latest Developments
12.6 Sellas
12.6.1 Sellas Company Information
12.6.2 Sellas Peptide Cancer Vaccine Product Offered
12.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Sellas Main Business Overview
12.6.5 Sellas Latest Developments
12.7 Imugene
12.7.1 Imugene Company Information
12.7.2 Imugene Peptide Cancer Vaccine Product Offered
12.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Imugene Main Business Overview
12.7.5 Imugene Latest Developments
12.8 VAXON Biotech
12.8.1 VAXON Biotech Company Information
12.8.2 VAXON Biotech Peptide Cancer Vaccine Product Offered
12.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 VAXON Biotech Main Business Overview
12.8.5 VAXON Biotech Latest Developments
12.9 Generex Biotechnology
12.9.1 Generex Biotechnology Company Information
12.9.2 Generex Biotechnology Peptide Cancer Vaccine Product Offered
12.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Generex Biotechnology Main Business Overview
12.9.5 Generex Biotechnology Latest Developments
12.10 ISA Pharmaceuticals
12.10.1 ISA Pharmaceuticals Company Information
12.10.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Offered
12.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 ISA Pharmaceuticals Main Business Overview
12.10.5 ISA Pharmaceuticals Latest Developments
12.11 OncoTherapy Science
12.11.1 OncoTherapy Science Company Information
12.11.2 OncoTherapy Science Peptide Cancer Vaccine Product Offered
12.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 OncoTherapy Science Main Business Overview
12.11.5 OncoTherapy Science Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Peptide Cancer Vaccine Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of ITK-1
Table 3. Major Players of GRN-1201
Table 4. Major Players of TPIV200
Table 5. Major Players of TPIV110
Table 6. Major Players of UV1
Table 7. Major Players of Galinpepimut-S
Table 8. Major Players of TARP 27-35
Table 9. Major Players of HER-Vaxx
Table 10. Major Players of Vx-001
Table 11. Major Players of Others
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 13. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Table 14. Global Peptide Cancer Vaccine Revenue by Pipeline (2016-2021) & ($ million)
Table 15. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2016-2021)
Table 16. Global Peptide Cancer Vaccine Sale Price by Pipeline (2016-2021)
Table 17. Global Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 18. Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 19. Global Peptide Cancer Vaccine Value by Application (2016-2021)
Table 20. Global Peptide Cancer Vaccine Revenue Market Share by Application (2016-2021)
Table 21. Global Peptide Cancer Vaccine Sale Price by Application (2016-2021)
Table 22. Global Peptide Cancer Vaccine Sales by Company (2019-2021) & (K Doses)
Table 23. Global Peptide Cancer Vaccine Sales Market Share by Company (2019-2021)
Table 24. Global Peptide Cancer Vaccine Revenue by Company (2019-2021) ($ Millions)
Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2021)
Table 26. Global Peptide Cancer Vaccine Sale Price by Company (2019-2021)
Table 27. Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution and Sales Area
Table 28. Players Peptide Cancer Vaccine Products Offered
Table 29. Peptide Cancer Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Peptide Cancer Vaccine Sales by Region (2016-2021) (K Doses)
Table 33. Global Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
Table 34. Global Peptide Cancer Vaccine Revenue by Region (2016-2021) & ($ Millions)
Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Region (2016-2021)
Table 36. Americas Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 37. Americas Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 38. Americas Peptide Cancer Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 39. Americas Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 40. Americas Peptide Cancer Vaccine Sales by Type (2016-2021) & (K Doses)
Table 41. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Table 42. Americas Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 43. Americas Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 44. APAC Peptide Cancer Vaccine Sales by Region (2016-2021) & (K Doses)
Table 45. APAC Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
Table 46. APAC Peptide Cancer Vaccine Revenue by Region (2016-2021) & ($ Millions)
Table 47. APAC Peptide Cancer Vaccine Revenue Market Share by Region (2016-2021)
Table 48. APAC Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 49. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Table 50. APAC Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 51. APAC Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 52. Europe Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 53. Europe Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 54. Europe Peptide Cancer Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 55. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 56. Europe Peptide Cancer Vaccine Sales by Type (2016-2021) & (K Doses)
Table 57. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Table 58. Europe Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 59. Europe Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 60. Middle East & Africa Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 61. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 62. Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 63. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 64. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 65. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Table 66. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 67. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 68. Key and Potential Regions of Peptide Cancer Vaccine
Table 69. Key Application and Potential Industries of Peptide Cancer Vaccine
Table 70. Key Challenges of Peptide Cancer Vaccine
Table 71. Key Trends of Peptide Cancer Vaccine
Table 72. Peptide Cancer Vaccine Distributors List
Table 73. Peptide Cancer Vaccine Customer List
Table 74. Global Peptide Cancer Vaccine Sales Forecast by Region (2021-2026) & (K Doses)
Table 75. Global Peptide Cancer Vaccine Consumption Market Forecast by Region
Table 76. Global Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026) & ($ millions)
Table 77. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Region (2021-2026)
Table 78. Americas Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) & (K Doses)
Table 79. Americas Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 80. APAC Peptide Cancer Vaccine Sales Forecast by Region (2021-2026) & (K Doses)
Table 81. APAC Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026) & ($ millions)
Table 82. Europe Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) & (K Doses)
Table 83. Europe Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 84. Middle East & Africa Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) & (K Doses)
Table 85. Middle East & Africa Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 86. Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2021-2026) & (K Doses)
Table 87. Global Peptide Cancer Vaccine Sales Market Share Forecast by Pipeline (2021-2026)
Table 88. Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2021-2026) & ($ Millions)
Table 89. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Pipeline (2021-2026)
Table 90. Global Peptide Cancer Vaccine Sales Forecast by Application (2021-2026) & (K Doses)
Table 91. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2021-2026)
Table 92. Global Peptide Cancer Vaccine Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 93. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2021-2026)
Table 94. Boston Biomedical Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Boston Biomedical Peptide Cancer Vaccine Product Offered
Table 96. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 97. Boston Biomedical Main Business
Table 98. Boston Biomedical Latest Developments
Table 99. Ultimovacs Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Ultimovacs Peptide Cancer Vaccine Product Offered
Table 101. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 102. Ultimovacs Main Business
Table 103. Ultimovacs Latest Developments
Table 104. BrightPath Biotherapeutics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Offered
Table 106. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 107. BrightPath Biotherapeutics Main Business
Table 108. BrightPath Biotherapeutics Latest Developments
Table 109. TapImmune Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. TapImmune Peptide Cancer Vaccine Product Offered
Table 111. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 112. TapImmune Main Business
Table 113. TapImmune Latest Developments
Table 114. Immatics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Immatics Peptide Cancer Vaccine Product Offered
Table 116. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 117. Immatics Main Business
Table 118. Immatics Latest Developments
Table 119. Sellas Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Sellas Peptide Cancer Vaccine Product Offered
Table 121. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 122. Sellas Main Business
Table 123. Sellas Latest Developments
Table 124. Imugene Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Imugene Peptide Cancer Vaccine Product Offered
Table 126. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 127. Imugene Main Business
Table 128. Imugene Latest Developments
Table 129. VAXON Biotech Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. VAXON Biotech Peptide Cancer Vaccine Product Offered
Table 131. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 132. VAXON Biotech Main Business
Table 133. VAXON Biotech Latest Developments
Table 134. Generex Biotechnology Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Generex Biotechnology Peptide Cancer Vaccine Product Offered
Table 136. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 137. Generex Biotechnology Main Business
Table 138. Generex Biotechnology Latest Developments
Table 139. ISA Pharmaceuticals Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. ISA Pharmaceuticals Peptide Cancer Vaccine Product Offered
Table 141. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 142. ISA Pharmaceuticals Main Business
Table 143. ISA Pharmaceuticals Latest Developments
Table 144. OncoTherapy Science Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. OncoTherapy Science Peptide Cancer Vaccine Product Offered
Table 146. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 147. OncoTherapy Science Main Business
Table 148. OncoTherapy Science Latest Developments
List of Figures
Figure 1. Picture of Peptide Cancer Vaccine
Figure 2. Peptide Cancer Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Cancer Vaccine Sales Growth Rate 2016-2026 (K Doses)
Figure 7. Global Peptide Cancer Vaccine Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Peptide Cancer Vaccine Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of ITK-1
Figure 10. Product Picture of GRN-1201
Figure 11. Product Picture of TPIV200
Figure 12. Product Picture of TPIV110
Figure 13. Product Picture of UV1
Figure 14. Product Picture of Galinpepimut-S
Figure 15. Product Picture of TARP 27-35
Figure 16. Product Picture of HER-Vaxx
Figure 17. Product Picture of Vx-001
Figure 18. Product Picture of Others
Figure 19. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 20. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2016-2021)
Figure 21. Peptide Cancer Vaccine Consumed in Breast Cancer
Figure 22. Global Peptide Cancer Vaccine Market: Breast Cancer (2016-2021) & (K Doses)
Figure 23. Peptide Cancer Vaccine Consumed in Lung Cancer
Figure 24. Global Peptide Cancer Vaccine Market: Lung Cancer (2016-2021) & (K Doses)
Figure 25. Peptide Cancer Vaccine Consumed in Melanoma
Figure 26. Global Peptide Cancer Vaccine Market: Melanoma (2016-2021) & (K Doses)
Figure 27. Peptide Cancer Vaccine Consumed in Prostate Cancer
Figure 28. Global Peptide Cancer Vaccine Market: Prostate Cancer (2016-2021) & (K Doses)
Figure 29. Peptide Cancer Vaccine Consumed in Others
Figure 30. Global Peptide Cancer Vaccine Market: Others (2016-2021) & (K Doses)
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Figure 32. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2020
Figure 33. Peptide Cancer Vaccine Revenue Market by Company in 2020 ($ Million)
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Company in 2020
Figure 35. Global Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Figure 36. Global Peptide Cancer Vaccine Revenue Market Share by Region in 2020
Figure 37. Americas Peptide Cancer Vaccine Sales 2016-2021 (K Doses)
Figure 38. Americas Peptide Cancer Vaccine Revenue 2016-2021 ($ Millions)
Figure 39. APAC Peptide Cancer Vaccine Sales 2016-2021 (K Doses)
Figure 40. APAC Peptide Cancer Vaccine Revenue 2016-2021 ($ Millions)
Figure 41. Europe Peptide Cancer Vaccine Sales 2016-2021 (K Doses)
Figure 42. Europe Peptide Cancer Vaccine Revenue 2016-2021 ($ Millions)
Figure 43. Middle East & Africa Peptide Cancer Vaccine Sales 2016-2021 (K Doses)
Figure 44. Middle East & Africa Peptide Cancer Vaccine Revenue 2016-2021 ($ Millions)
Figure 45. Americas Peptide Cancer Vaccine Sales Market Share by Country in 2020
Figure 46. Americas Peptide Cancer Vaccine Revenue Market Share by Country in 2020
Figure 47. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 48. Americas Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 49. United States Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 50. Canada Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 51. Mexico Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 52. Brazil Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 53. APAC Peptide Cancer Vaccine Sales Market Share by Region in 2020
Figure 54. APAC Peptide Cancer Vaccine Revenue Market Share by Regions in 2020
Figure 55. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 56. APAC Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 57. China Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 58. Japan Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 59. Korea Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 60. Southeast Asia Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 61. India Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 62. Australia Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 63. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2020
Figure 64. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2020
Figure 65. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 66. Europe Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 67. Germany Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 68. France Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 69. UK Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 70. Italy Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 71. Russia Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 72. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country in 2020
Figure 73. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country in 2020
Figure 74. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 75. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 76. Egypt Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 77. South Africa Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 78. Israel Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 79. Turkey Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 80. GCC Country Peptide Cancer Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
